ZA99476B - Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion. - Google Patents

Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion.

Info

Publication number
ZA99476B
ZA99476B ZA9900476A ZA99476A ZA99476B ZA 99476 B ZA99476 B ZA 99476B ZA 9900476 A ZA9900476 A ZA 9900476A ZA 99476 A ZA99476 A ZA 99476A ZA 99476 B ZA99476 B ZA 99476B
Authority
ZA
South Africa
Prior art keywords
inhibitors
cell adhesion
bone resorption
sulfonamide derivatives
novel sulfonamide
Prior art date
Application number
ZA9900476A
Other languages
English (en)
Inventor
Anuschirwan Peyman
David William Will
Jochen Knolle
Karlheinz Scheunemann
Denis Carniato
Jean-Francois Gourvest
Thomas R Gadek
Robert Mcdowell
Sarah Catherine Bodary
Robert Andrew Cuthbertson
Original Assignee
Hoechst Marion Roussel De Gmbh
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel De Gmbh, Genentech Inc filed Critical Hoechst Marion Roussel De Gmbh
Publication of ZA99476B publication Critical patent/ZA99476B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA9900476A 1998-01-23 1999-01-22 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion. ZA99476B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23

Publications (1)

Publication Number Publication Date
ZA99476B true ZA99476B (en) 1999-08-05

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9900476A ZA99476B (en) 1998-01-23 1999-01-22 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion.

Country Status (25)

Country Link
EP (1) EP1049677A1 (cg-RX-API-DMAC7.html)
JP (1) JP2002501054A (cg-RX-API-DMAC7.html)
KR (1) KR20010034319A (cg-RX-API-DMAC7.html)
CN (1) CN1177832C (cg-RX-API-DMAC7.html)
AP (1) AP1269A (cg-RX-API-DMAC7.html)
AR (1) AR014456A1 (cg-RX-API-DMAC7.html)
AU (1) AU752882B2 (cg-RX-API-DMAC7.html)
BG (1) BG104630A (cg-RX-API-DMAC7.html)
BR (1) BR9907735A (cg-RX-API-DMAC7.html)
CA (1) CA2318221A1 (cg-RX-API-DMAC7.html)
EA (1) EA003102B1 (cg-RX-API-DMAC7.html)
HR (1) HRP20000493A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0100520A3 (cg-RX-API-DMAC7.html)
ID (1) ID26219A (cg-RX-API-DMAC7.html)
IL (1) IL137423A0 (cg-RX-API-DMAC7.html)
NO (1) NO318795B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ505613A (cg-RX-API-DMAC7.html)
PL (1) PL341871A1 (cg-RX-API-DMAC7.html)
SK (1) SK10632000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200002160T2 (cg-RX-API-DMAC7.html)
TW (1) TWI247742B (cg-RX-API-DMAC7.html)
UA (1) UA63990C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999037621A1 (cg-RX-API-DMAC7.html)
YU (1) YU47200A (cg-RX-API-DMAC7.html)
ZA (1) ZA99476B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1070707A1 (en) 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
AU2207001A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel compounds and process
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
EP1727811B1 (en) 2004-03-24 2014-11-12 Shire Orphan Therapies GmbH New compounds for the inhibition of angiogenesis and use of thereof
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
ES2864079T3 (es) 2014-05-30 2021-10-13 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
HUE057569T2 (hu) 2014-12-17 2022-05-28 Pimco 2664 Ltd N-(4-hidroxi-4-metil-ciklohexil)-4-fenil-benzolszulfonamid és N-(4-hidroxi-4-metil-ciklohexil)-4-(2-piridil)-benzolszulfonamid vegyületek és terápiás alkalmazásuk
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE227567T1 (de) * 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
JP3895792B2 (ja) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス 骨形成促進剤

Also Published As

Publication number Publication date
IL137423A0 (en) 2001-07-24
AU752882B2 (en) 2002-10-03
HRP20000493A2 (en) 2001-06-30
BG104630A (en) 2001-04-30
TR200002160T2 (tr) 2001-07-23
YU47200A (sh) 2002-11-15
WO1999037621A1 (en) 1999-07-29
SK10632000A3 (sk) 2001-02-12
AP2000001863A0 (en) 2000-09-30
AR014456A1 (es) 2001-02-28
BR9907735A (pt) 2000-10-17
NO20003765L (no) 2000-09-25
HUP0100520A1 (hu) 2001-07-30
JP2002501054A (ja) 2002-01-15
ID26219A (id) 2000-12-07
EA003102B1 (ru) 2002-12-26
AU2518199A (en) 1999-08-09
HUP0100520A3 (en) 2002-11-28
EP1049677A1 (en) 2000-11-08
CA2318221A1 (en) 1999-07-29
EA200000785A1 (ru) 2001-02-26
NO318795B1 (no) 2005-05-09
UA63990C2 (uk) 2004-02-16
NO20003765D0 (no) 2000-07-21
KR20010034319A (ko) 2001-04-25
TWI247742B (en) 2006-01-21
NZ505613A (en) 2002-11-26
AP1269A (en) 2004-04-03
CN1293662A (zh) 2001-05-02
PL341871A1 (en) 2001-05-07
CN1177832C (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
HUP0100520A3 (en) Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
AU3359697A (en) Bone resorption inhibitors
AU5239399A (en) Antisense modulation of g-alpha-13 expression
AU5587499A (en) Antisense modulation of g-alpha-16 expression
AU2002227435A1 (en) Antisense modulation of calreticulin expression
AU5991699A (en) Quinolizinones as integrin inhibitors
AU3064699A (en) Dynamic orthopedic braces
IL138387A0 (en) Enzyme inhibitors
AU2003281327A1 (en) Antisense modulation of tfg-beta 2 expression
AU4138599A (en) Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
AU7928898A (en) Determination of acoustic velocity in bone
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
AU6330199A (en) Electrochemical synthesis of perfluoroalkylfluorophosphoranes
AU2190400A (en) Inhibitors of beta-lactamases and uses therefor
AU1486997A (en) An agent promoting bone formation and inhibiting bone resorption
AU3716499A (en) Substituted diamines and their use as cell adhesion inhibitors
HUP0101640A3 (en) Certain thoil inhibitors of endothelin-converting enzyme
AU5321199A (en) Antisense modulation of inhibitor-kappa b kinase-beta expression
AU5222899A (en) Antisense modulation of inhibitor-kappa b kinase-alpha expression
AU4442799A (en) Antisense modulation of elk-1 expression
AU9312598A (en) Inhibitors of collagen assembly
AU2832399A (en) B cell inhibitors
AU3110500A (en) Cell matrix plaques of initial bone formation
AUPO907697A0 (en) Chemical supplementation of bone
AU2517399A (en) Utilization of substituted sulfonamides as antiviral agents and novel substances